119 citations
,
May 2020 in “Journal of The American Academy of Dermatology” This study observed a high prevalence of androgenetic alopecia in patients hospitalized with severe COVID-19, with 79% of men and 42% of women affected, suggesting a potential link between androgen sensitivity and COVID-19 severity.
112 citations
,
July 2020 in “BMC Medicine” This review discusses how overlapping risk factors in women with polycystic ovary syndrome may heighten their risk for severe COVID-19, advocating for integrated care approaches but provides no new clinical results.
102 citations
,
January 2022 in “Mayo Clinic Proceedings” This review highlights that long-term health consequences of COVID-19, affecting multiple body systems, persist after acute infection, necessitating a comprehensive management approach that includes interdisciplinary care and lifestyle interventions to mitigate long-term damage.
82 citations
,
September 2020 in “Briefings in Bioinformatics” This study identified shared genes and pathways in idiopathic pulmonary fibrosis patients with COVID-19, suggesting these may increase mortality and pointing to potential drug targets for treatment.
70 citations
,
April 2020 in “Journal of Molecular Cell Biology” This review summarizes recent advances in organoid technology for generating tissue models from the three germ layers and reports no new experimental results.
69 citations
,
June 2016 in “Journal of Investigative Dermatology” This study found sebaceous gland atrophy and altered gene expression in psoriatic skin lesions, which may relate to the observed hair loss in these areas.
55 citations
,
April 2022 in “Frontiers in Immunology” This review examines the role of cholesterol metabolism in coronavirus infections, discussing its potential as a target for antiviral strategies and a marker for monitoring infection status, but presents no new results.
55 citations
,
October 2020 in “Frontiers in Pharmacology” This review discusses the role of endolysosomes in SARS-CoV-2 infection and COVID-19 pathogenesis, and explores potential therapeutic strategies targeting these cellular structures, but reports no new clinical findings.
52 citations
,
August 2021 in “Microorganisms” This review observes higher ACE2 expression in myocardial and lung tissues of heart failure and COPD patients but finds no link between RAAS inhibitors and COVID-19 severity.
52 citations
,
January 2021 in “Journal of Thoracic Oncology” Effective vaccines and treatments are crucial for long-term COVID-19 control.
48 citations
,
August 2022 in “Chemical Biology & Drug Design” This review outlines computational strategies, including chemogenomics and drug repositioning, for coronavirus drug discovery and reports no new clinical findings; the authors highlight the advantages of these methods in rapidly identifying therapeutic candidates.
42 citations
,
April 2021 in “Pharmaceuticals” This study identified five FDA-approved drugs—cepharantine, clofazimine, metergoline, imatinib, and efloxate—as potential candidates for repurposing to interfere with viral entry in COVID-19 treatment.
41 citations
,
June 2023 in “Antioxidants” This review highlights that pomegranate exhibits promising beneficial effects in preclinical and clinical studies for cardiovascular and non-cardiovascular diseases, though further research is needed on its bioavailability and metabolites for effective therapeutic use.
35 citations
,
May 2023 in “International Journal of Preventive Medicine” This review discusses the various aspects of long COVID, highlighting its multi-organ impact, including symptoms like fatigue and dyspnea, and suggests that vaccination may play a role in prevention and management. Risk factors and potential therapeutic strategies are also examined.
29 citations
,
November 2021 in “FEBS Open Bio” In this study, molecular docking simulations and cell-based assays suggested that certain analogues of cepharanthine might possess anti-SARS-CoV-2 activity.
29 citations
,
March 2021 in “Frontiers in Endocrinology” This review discusses the dual role of testosterone in COVID-19 progression and suggests its importance in understanding the disease's mechanisms, highlighting the need for further targeted research.
28 citations
,
February 2021 in “Open Forum Infectious Diseases” This review highlights how social, environmental, and biological factors combine to increase COVID-19 risks in the African American community, emphasizing the need to understand these complex disparities; it reports no new results.
25 citations
,
February 2022 in “JAAD International” This review analyzed data on alopecia types associated with COVID-19, suggesting androgenetic alopecia may be a risk factor for severe COVID-19, while telogen effluvium often follows infection and alopecia areata tends to relapse in those with preexisting disease.
25 citations
,
August 2021 in “Irish Journal of Medical Science (1971 -)” This study found that COVID-19 infection is a frequent cause of acute telogen effluvium, leading to excessive hair loss within 2–3 months after infection.
24 citations
,
December 2020 in “Kardiologiia” This study found that combining bromhexine and spironolactone was effective in improving clinical outcomes and reducing viral load or hospitalization duration in patients with mild to moderate COVID-19.
22 citations
,
January 2021 in “Clinical Therapeutics” This review discusses sex and gender differences in COVID-19 presentation, treatment, and outcomes, and reports no new clinical findings.
19 citations
,
December 2021 in “Cureus” This study found that proxalutamide significantly increased recovery rates, reduced mortality, and shortened hospital stays in hospitalized COVID-19 patients across different regions in Brazil.
19 citations
,
November 2021 in “Reviews in endocrine and metabolic disorders” This article discusses the role of sex hormones in COVID-19 fatality differences between sexes and reports no new clinical results, suggesting that future strategies should consider sex-specific approaches.
18 citations
,
November 2021 in “Anais Brasileiros de Dermatologia” This review examines the skin manifestations associated with COVID-19 but reports no new clinical findings, emphasizing the need for differential diagnoses to correlate skin symptoms with the virus.
17 citations
,
January 2023 in “Frontiers in Cell and Developmental Biology” This review discusses methods for generating induced pluripotent stem cells and highlights their recent applications in studying and treating COVID-19, but it reports no new experimental results.
16 citations
,
November 2020 in “PLOS ONE” This study found that lack of sleep, increased physical activity, and alopecia were associated with a higher risk of COVID-19 infection, while low-dose alcohol intake, hand hygiene, and daily fruit consumption were linked to reduced morbidity.
15 citations
,
July 2022 in “Frontiers in Pharmacology” This study suggests that Cepharanthine, a monomer in traditional Chinese medicine, may help treat COVID-19 by affecting multiple signaling pathways, and that TNF and IL-17 inhibitors used in rheumatoid arthritis, ankylosing spondylitis, and gouty arthritis might also be beneficial.
14 citations
,
April 2021 in “Clinical, Cosmetic and Investigational Dermatology” This report describes a case of acute telogen effluvium in a 38-year-old woman following recovery from COVID-19.
13 citations
,
September 2023 in “Medical Gas Research” This review explores the molecular mechanisms and potential roles of nitric oxide in COVID-19 therapy, but provides no new clinical results.
13 citations
,
July 2022 in “International Journal of Environmental Research and Public Health” This study found that while male COVID-19 patients in Brazil exhibited more severe symptoms and required more intensive care than females, the difference in risk of death was relatively small.